secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-06-11T23:59:59+00:00
Accession:  0001193125-25-139164
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio announces FDA approval of IBTROZI (taletrectinib) for ROS1+ NSCLC
------------------------------------------------------------------------------

- FDA approved IBTROZI for adult patients with locally advanced or metastatic ROS1+ NSCLC.
- In TRUST-I, cORR of 90% in TKI-naïve patients; TRUST-II cORR of 85%; median DOR not yet reached.
- Intracranial response in 73% of TKI-naïve and 63% of TKI-pretreated patients with brain metastases.
- Generally well-tolerated; 7% discontinued due to TEAEs; most common AEs: diarrhea (64%), nausea (47%), vomiting (43%).
- Approved dose 600 mg once-daily; half-life ~66 hours enabling sustained CNS exposure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525139164/0001193125-25-139164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525139164/d932856d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-139164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer